Tevogen Targets $20M Revenue Boost with CRO Acquisition
Tevogen Bio Holdings (Nasdaq: TVGN) announced on March 26, 2026, that it is in the advanced stages of evaluating a niche contract research organization (CRO) for a potential acquisition. The deal is projected to contribute more than $20 million in annual revenue and support double-digit growth starting next year. This move is a critical step in Tevogen's strategy to become a more diversified, revenue-generating healthcare company.
The target CRO operates in over 20 countries and has established relationships in the high-value sectors of oncology, rare diseases, and medical devices. Acquiring this global footprint and specialized expertise would significantly enhance Tevogen's clinical research delivery capabilities and support its long-term goal of building a scalable, cash-flow-oriented operating model.
Move Follows Regaining Nasdaq $1.00 Price Compliance
This strategic announcement comes just one day after Tevogen resolved a key market concern. On March 25, 2026, the company received notification from Nasdaq that it had regained compliance with the exchange's $1.00 minimum bid price requirement. Tevogen had previously been out of compliance with the listing rule since September 23, 2025. Securing its listing status provides a stable foundation from which the company can now pursue aggressive growth initiatives like the CRO acquisition.
CEO Eyes Path to $100M Annual Revenue
Tevogen's leadership views the potential CRO deal as a foundational piece of a much larger growth plan. The company is actively reviewing additional acquisition opportunities to accelerate its transition into a cash-flow-positive enterprise. CEO Dr. Ryan Saadi framed the larger ambition for investors.
With the advanced-stage evaluation of this CRO, alongside additional acquisition opportunities under review, there may be potential to generating closer to $100 million in annual revenue, I hope to update further in the near term.
— Dr. Ryan Saadi, CEO, Tevogen Bio.
This statement positions the initial $20 million revenue target as a stepping stone in a broader strategy. The company aims to use these acquisitions to fund its core mission of developing its proprietary ExacTcell™ therapy platform and Tevogen.AI drug development technologies while maintaining fiscal independence.
